Literature DB >> 15240689

T cell immunity induced by live, necrotic, and apoptotic tumor cells.

Wolf C Bartholomae1, Frauke H Rininsland, Julia C Eisenberg, Bernhard O Boehm, Paul V Lehmann, Magdalena Tary-Lehmann.   

Abstract

The rules that govern the engagement of antitumor immunity are not yet fully understood. Ags expressed by tumor cells are prone to induce T cell tolerance unless the innate immune system is activated. It is unclear to what extent tumors engage this second signal link by the innate immune system. Apoptotic and necrotic (tumor) cells are readily recognized and phagocytosed by the cells of the innate immune system. It is unknown how this affects the tumor's immunogenicity. Using a murine melanoma (B16m) and lymphoma (L5178Y-R) model, we studied the clonal sizes and cytokine signatures of the T cells induced by these tumors in syngeneic mice when injected as live, apoptotic, and necrotic cells. Both live tumors induced a type 2 CD4 cell response characterized by the prevalent production of IL-2, IL-4, and IL-5 over IFN-gamma. Live, apoptotic, and necrotic cells induced CD4 (but no CD8) T cells of comparable frequencies and cytokine profiles. Therefore, live tumors engaged the second signal link, and apoptotic or necrotic tumor cell death did not change the magnitude or quality of the antitumor response. A subclone of L5178Y-R, L5178Y-S cells, were found to induce a high-frequency type 1 response by CD4 and CD8 cells that conveyed immune protection. The data suggest that the immunogenicity of tumors, and their characteristics to induce type 1 or type 2, CD4 or CD8 cell immunity is not primarily governed by signals associated with apoptotic or necrotic cell death, but is an intrinsic feature of the tumor itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240689     DOI: 10.4049/jimmunol.173.2.1012

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

Authors:  Martin K Hunn; Evelyn Bauer; Catherine E Wood; Olivier Gasser; Marina Dzhelali; Lindsay R Ancelet; Brigitta Mester; Katrina J Sharples; Michael P Findlay; David A Hamilton; Ian F Hermans
Journal:  J Neurooncol       Date:  2014-10-31       Impact factor: 4.130

Review 2.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

3.  Triple approach strategy for patients with locally advanced pancreatic carcinoma.

Authors:  Alessandro Giardino; Roberto Girelli; Isabella Frigerio; Paolo Regi; Maurizio Cantore; Auriemma Alessandra; Annita Lusenti; Roberto Salvia; Claudio Bassi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2012-12-06       Impact factor: 3.647

4.  Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Cancer Immun       Date:  2013-01-15

Review 5.  Immunogenicity of necrotic cell death.

Authors:  Jaba Gamrekelashvili; Tim F Greten; Firouzeh Korangy
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

Review 6.  Oncolytic viruses: a novel form of immunotherapy.

Authors:  Robin J Prestwich; Kevin J Harrington; Hardev S Pandha; Richard G Vile; Alan A Melcher; Fiona Errington
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

Review 7.  Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Authors:  Nathalie Chaput; Stéphane De Botton; Michel Obeid; Lionel Apetoh; François Ghiringhelli; Theocharis Panaretakis; Caroline Flament; Laurence Zitvogel; Guido Kroemer
Journal:  J Mol Med (Berl)       Date:  2007-05-22       Impact factor: 4.599

8.  Limiting glioma development by photodynamic therapy-generated macrophage vaccine and allo-stimulation: an in vivo histological study in rats.

Authors:  Steen J Madsen; Catherine Christie; Khoi Huynh; Qian Peng; Francisco A Uzal; Tatiana B Krasieva; Henry Hirschberg
Journal:  J Biomed Opt       Date:  2018-02       Impact factor: 3.170

9.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Authors:  Noelia Casares; Marie O Pequignot; Antoine Tesniere; François Ghiringhelli; Stéphan Roux; Nathalie Chaput; Elise Schmitt; Ahmed Hamai; Sandra Hervas-Stubbs; Michel Obeid; Frédéric Coutant; Didier Métivier; Evelyne Pichard; Pierre Aucouturier; Gérard Pierron; Carmen Garrido; Laurence Zitvogel; Guido Kroemer
Journal:  J Exp Med       Date:  2005-12-19       Impact factor: 14.307

Review 10.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses.

Authors:  Tania Løve Aaes; Peter Vandenabeele
Journal:  Cell Death Differ       Date:  2020-11-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.